Randomised controlled trialindependent cross-checkabstract checked★ key study I-GRN-107 in-depth review
Even 50 mg of gluten a day harms the gut in coeliac disease
A prospective, double-blind, placebo-controlled trial to establish a safe gluten threshold for patients with celiac disease.
Overview
Catassi C et al.. Am J Clin Nutr 2007 · PMID 17209192 · DOI 10.1093/ajcn/85.1.160
In treated coeliac patients, 50 mg gluten daily for 3 months reduced villus height by about 20%; placebo did not.
Does the study support the specific claim? No · Methodological quality: moderate
Plain-language summary
Study explained simply
- What did the researchers want to find out?
Find a safe trace-gluten level.
- How was the study done?
Randomised blinded capsule trial.
- How many people, animals or samples were studied?
49 adults with coeliac disease.
- What was actually found?
50 mg/day damaged villi.
- How large was the observed effect?
-20% Vh/Cd vs +9% on placebo.
- What do the results mean in everyday life?
Strictness matters: small amounts are harmful.
- What are the study's limitations?
Small, short.
- What does it say about Elawady's specific claim?
Contradicts reintroducing gluten; supports gluten-free standards.
- Do the results apply to Germany and Europe?
Basis of EU limit.
- What can explicitly not be concluded from this study?
Does not define risk for each individual.
Scientific in-depth review
1. Full reference
- Authors
- Catassi C et al.
- Journal
- Am J Clin Nutr
- Year
- 2007
- Identifier
- PMID 17209192 DOI 10.1093/ajcn/85.1.160
- Verification
- verified – PubMed efetch 2026-10-26; Crossref works API 2026-10-26
- Retracted
- no
- Corrections
- none
- Extent checked
- abstract only
- Conflicts of interest and funding
not stated in abstract/PubMed record
2. Research question
What is a safe daily amount of contaminating gluten for treated coeliac patients?
3. Study design and population
- Study design
- Randomised controlled trial – Multicentre randomised double-blind placebo-controlled trial (gluten microchallenge)
- Population
Adults with biopsy-proven coeliac disease on a gluten-free diet for >=2 years
- Country
not stated in abstract (multicentre)
- Period
not stated in abstract
- Sample size
49 randomised (13 analysed per group at follow-up biopsy)
- Inclusion and exclusion criteria
Background gluten intake <5 mg/day
4. Methods and endpoints
- Exposure / intervention
Daily capsule with 10 mg or 50 mg gluten for 90 days
- Comparator
Placebo capsule
- Endpoints
Villous height/crypt depth (Vh/Cd), intraepithelial lymphocytes, serology, clinical relapse
- Statistical methods
Within-group percentage change
5. Actual results
- Results
Change in Vh/Cd: placebo +9% (3% to 15%), 10 mg -1% (-18% to 68%), 50 mg -20% (-22% to -13%). One patient on 10 mg had a clinical relapse. No significant differences in IEL count.
- Absolute risks
not reported
- Authors' conclusion
Ingestion of contaminating gluten should be kept lower than 50 mg/day in the treatment of coeliac disease.
6. Strengths
- Randomised, double-blind, placebo-controlled
- Histological endpoint
7. Weaknesses
- Small groups
- Only 90 days
- Wide CI in 10 mg group
8. Risk of bias
- Orienting tool
- RoB 2
- Type of assessment
- simplified assessment (abstract only)
- Full formal assessment
- no
- Overall risk of bias
- some concerns
- Rationale
Small sample; attrition from 49 to 39 analysed.
9. Assessment of the statistical interpretation
50 mg/day (about 1/50 to 1/100 of a slice of bread, order of magnitude) measurably damaged the mucosa within 3 months.
10. Relevance to the specific claim
Even tiny amounts of gluten damage the intestine in coeliac disease; basis of the 20 ppm gluten-free limit.
11. Independent contrary findings
Individual tolerance varies (letter PMID 17616789).
12. Transferability to Germany and Europe
High; basis for EU/Codex 20 ppm standard.
13. Overall methodological judgement
Key trial for the safety threshold.
| Multidimensional assessment | |
|---|---|
| Authenticity of the source | verified |
| Methodological quality | moderate |
| Risk of bias | some concerns |
| Precision of results | low |
| Directness | direct |
| Reproducibility | partly replicated |
| Consistency with the overall evidence | consistent |
| Regional transferability | high |
| Adequacy of the interpretation (by the archive) | not applicable |
14. Open questions
Long-term effects of 10 mg/day.
15. Linked fact checks
- In a joint live stream on Elawady's channel, a speaker (Elawady or his guest Dr. Tamer El-Baz; speaker turns cannot be identified) describes a coeliac patient on the system who reintroduced gluten-containing toast, and advises pausing it when symptoms appear and reintroducing it later. – Studies contradicting or limiting the claim
- Gluten is present in all grains, including oats, rice and maize, so 'gluten-free' bread or flour is a meaningless concept. – Studies contradicting or limiting the claim